Last Updated: November 13, 2026

Strides Pharma Intl Company Profile

« Back to Dashboard

What is the competitive landscape for STRIDES PHARMA INTL

STRIDES PHARMA INTL has one hundred and ten approved drugs.

There are five US patents protecting STRIDES PHARMA INTL drugs.

Summary for Strides Pharma Intl

US Patents:	5
Tradenames:	75
Ingredients:	72
NDAs:	110

Drugs and US Patents for Strides Pharma Intl

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Strides Pharma Intl	DOXYCYCLINE HYCLATE	doxycycline hyclate	TABLET;ORAL	062538-002	Nov 24, 2025	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Strides Pharma Intl	ISOSORBIDE MONONITRATE	isosorbide mononitrate	TABLET, EXTENDED RELEASE;ORAL	090598-001	Aug 11, 2010		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Strides Pharma Intl	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	205001-002	Jul 5, 2016		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Strides Pharma Intl	METHYLDOPA AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; methyldopa	TABLET;ORAL	070614-002	Feb 2, 1987		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Strides Pharma Intl	LETROZOLE	letrozole	TABLET;ORAL	090789-001	Jun 3, 2011		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Strides Pharma Intl

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Strides Pharma Intl	ACCOLATE	zafirlukast	TABLET;ORAL	020547-003	Sep 17, 1999	6,143,775	⤷ Start Trial
Strides Pharma Intl	ACCOLATE	zafirlukast	TABLET;ORAL	020547-003	Sep 17, 1999	4,859,692	⤷ Start Trial
Strides Pharma Intl	ACCOLATE	zafirlukast	TABLET;ORAL	020547-003	Sep 17, 1999	5,482,963	⤷ Start Trial
Strides Pharma Intl	ACCOLATE	zafirlukast	TABLET;ORAL	020547-001	Sep 26, 1996	5,319,097	⤷ Start Trial
Strides Pharma Intl	ACCOLATE	zafirlukast	TABLET;ORAL	020547-001	Sep 26, 1996	5,583,152	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for STRIDES PHARMA INTL drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	10 mg and 20 mg	➤ Subscribe	2008-02-29

International Patents for Strides Pharma Intl Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Japan	7444967	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2021021277	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2023055457	⤷ Start Trial
Mexico	2022001139	⤷ Start Trial
Japan	7444967	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Strides Pharma Intl Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0984957	300483	Netherlands	⤷ Start Trial	PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYDRAAT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105
0716606	SPC/GB02/011	United Kingdom	⤷ Start Trial	PRODUCT NAME: SEVELAMER; REGISTERED: UK EU/1/99/120/001-004 20000202
0565634	06C0030	France	⤷ Start Trial	PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0521471	SPC/GB03/033	United Kingdom	⤷ Start Trial	PRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
0521471	C300125	Netherlands	⤷ Start Trial	PRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.